Experimental Therapies in Breast Cancer

Part of the Medical Radiology book series (MEDRAD)


Advancement of radiation-based breast cancer therapy is driven by highly strategic approaches to target diseased tissue. As a core premise, radiation therapy is designed to maximize therapeutic potential while minimizing harm to surrounding healthy tissue. Recently, advances in material design, synthesis, and characterization have lead to a surge in the number of approaches intended to shrink or eliminate the tumor burden of breast cancer. These latest advancements serve as the focus of the following chapter. While the topic is broad in nature, this review will emphasize the latest advancements in molecular-based and gene-based targeting, intralesional and intraoperative designs, and, importantly, the expanding sphere of nanomaterials. The topic of nanoscale materials will be developed to include approaches of organic-based systems, inorganic-based systems, and biological hybrid nanomaterials.


Breast Cancer Treatment Folate Receptor PAMAM Dendrimer Accelerate Partial Breast Irradiation Alternate Magnetic Field 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahn P, Vu H, Lannin D, Obedian E, DiGiovanna M, Burtness B et al (2005) Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23(1):17–23PubMedGoogle Scholar
  2. Alexiou C, Tietze R, Schreiber E, Jorgons R (2010) Cancer therapy with drug loaded magnetic nanoparticles-magnetic drug targeting. J Magn Magn Mater 323(10):1404–1407Google Scholar
  3. Alivisatos PA (1996) Semiconductor clusters, nanocrystals, and quantum dots. Science 271:933Google Scholar
  4. Arora H, Jensen M, Yuan Y, Wo A, Vogt S, Paunesku T et al (2012) Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res 72(3):769–778PubMedCentralPubMedGoogle Scholar
  5. Astsaturov I, Cohen R, Harari P (2007) EGRF-targeting monocolonal antibodies in head and neck cancer. Curr Cancer Drug Targets 7:650–665PubMedGoogle Scholar
  6. Balogh L (2010) Why do we have so many definitions for nanoscience and nanotechnology? Nanomed Nanotechnol Biol Med 6:397–398Google Scholar
  7. Balogh L, Nigavekar S, Nair B, Lesniak W, Zhang C, Sung L (2007) Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomed Nanotechnol Biol Med 3:281–296Google Scholar
  8. Bedi D, Musacchio T, Fagbohun O, Gillespie J, Deinnocentes P, Brid C et al (2011) Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. Nanomed Nanotechnol Biol Med 7(315):323Google Scholar
  9. Bhatt R, de Vries P, Tulinsky J (2003) Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugaes of 20S-camptothecin. J Med Chem 46:190–193PubMedGoogle Scholar
  10. Bhattacharyya S, Kudgus R, Bhattachrya R, Mukherjee P (2011) Inorganic nanoparticles in cancer therapy. Pharm Res 28:237–259PubMedCentralPubMedGoogle Scholar
  11. Bhirde A, Xie J, Swierczewska M, Chen M (2011) Nanoparticles for cell labeling. Nanoscale 3(142):153Google Scholar
  12. Bickford L, Agollah G, Drezek R, Yu T (2008) Evaluation of immunotargeted gold nanoshells as rapid diagnostic imaging agents for HER2-overexpressing breast cancer cells: a time-based analysis. Nanobiotechnology 4:1–8Google Scholar
  13. Bickford L, Agollah G, Drezek R, Yu T (2010) Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared confocal microscopy. Breast Cancer Res Treat 120:547–555PubMedGoogle Scholar
  14. Bouclier C, Marsaud V, Bawa O, Nicolas V, Moine L (2010) Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor α and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts. Breast Cancer Res Treat 122:145–158PubMedGoogle Scholar
  15. Cho B, Hurkman C, Damen E (2002) Intensity modulated versus non-intensity modulated radiotherapy in the treatment of the left breast and upper internal mammary lymph node chain: a comparative planning study. Radiother Oncol 62:127–136PubMedGoogle Scholar
  16. Cho K, Wang X, Nie S (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–1316PubMedGoogle Scholar
  17. Conde J, Doria G, Baptista P (2011) Noble metal nanoparticles applications in cancer. J Drug Deliv 2012: in pressGoogle Scholar
  18. de Lopes Menezes D, Mayer L (2002) Pharmacokinetics of Bcl-2 antisense oligonuclieotide (GS3139) combined with doxorubicin in scid mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol 49:57–68Google Scholar
  19. DeNardo S, DeNardo G, Miers L, Natarajan A, Foreman A (2011) Development of tumor targeting bioprobes (111-In chimeric l6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 11:7087s–7092sGoogle Scholar
  20. Dickler A, Kirk M, Seif N (2007) A dosimetric comparison of mammosite high-dose-rate brachytherapy and xoft axxent electronic brachytherapy. Brachytherapy 6(2):164–168PubMedGoogle Scholar
  21. Dooley W, Wurzer J, Megahy M, Schreiber G, Roy T, Prouix G (2011) Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis. OncoTargets Ther 4:13–20Google Scholar
  22. Eifel P, Axelson J, Costa J, Crowley J, Curran W (2000) National institutes of health consensus development conference statement: adjuvant therapy for breast cancer. J Nat Cancer Inst 93(13):979–989Google Scholar
  23. El-Sayed M, Kiani M, Naimark M, Hikal A, Ghandehari H (2001) Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium. Pharm Res 18:23–28PubMedGoogle Scholar
  24. Farokhzad O, Chenng J, Telpy B, Sherifi I, Jon S, Kantoff P et al (2006) Targeted Nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Nat Acad Sci 103(16):16315–16320Google Scholar
  25. Fisher B, Anderson S, Bryant J (2002a) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMedGoogle Scholar
  26. Fisher B, Bryant J, Dignam J (2002b) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20(20):4141–4149PubMedGoogle Scholar
  27. Fyles A, McCready D, Manchul L (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early stage breast cancer. N Engl J Med 351:963–970PubMedGoogle Scholar
  28. Gradishar W, Tjulandin S, Davidson N (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803PubMedGoogle Scholar
  29. Green J, Chiu E, Leschiner E, Langer R, Anderson D (2007) Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett 7:874–879PubMedGoogle Scholar
  30. Gruttner C, Muller K, Westphal F, Foreman A, Ivkov R (2007) Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. J Magn Magn Mater 311(1):181–186Google Scholar
  31. Haffty B, Kim J, Yang Q, Higgins S (2006) Concurrent chemo-radiation in the conservative management of breast cancer. Int J Radiat Oncol Biol Phys 66(5):1306–1312PubMedGoogle Scholar
  32. Hainfeld J, Slatkin D, Smilowitz H (2004) The use of gold nanoparticles to enhance radiotherarpy in mice. Phys Med Biol 49:309–315Google Scholar
  33. Hallahan D, Mauceri H, Seung L, Dunphy E, Wayne J, Hanna N et al (1995) Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1(8):786–791PubMedGoogle Scholar
  34. Hariri G, Yan H, Wang H, Han Z, Hallahan D (2010) Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res 16(20):4968–4977PubMedCentralPubMedGoogle Scholar
  35. Hariri G, Wellons M, Morris W, Lukehart C, Hallahan D (2011) Multifunctional FePt nanoparticles for radiation-guided targeting and imaging of cancer. Ann Biomed Eng 39(3):946–952PubMedCentralPubMedGoogle Scholar
  36. Harris E, Christensen V, Hwang W, Fox K, Solin L (2005) Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23(1):11–16PubMedGoogle Scholar
  37. Herold D, Das I, Stobbe C, Iyer R, Chapman J (2000) Gold microspheres: a selective technique for producing biologically effective dose enhancement. Int J Radiat Biol 76:1357–1364PubMedGoogle Scholar
  38. Hoffman A (2008) The origins and evolution of “controlled” drug delivery systems. J Controlled Release 132:153–163Google Scholar
  39. Hofheinz R, Gnad-Vogt S, Beyer U, Hochhaus A (2005) Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16:691–707PubMedGoogle Scholar
  40. Holli K, Hietanen P, Saaristo R, Huhtala H (2009) Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol 27(6):927–932PubMedGoogle Scholar
  41. Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Batti T et al (2010) Porous metal-organic-framework nanoscale carries as a potential platform for drug delivery and imaging. Nat Mater 9:172–178PubMedGoogle Scholar
  42. Hughes K, Schnaper L, Berry D (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. NEJM 351:971–977PubMedGoogle Scholar
  43. Jamison T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian A (2007) Biological applications of quantum dots. Biomaterials 28:4717–4732Google Scholar
  44. Janes K, Fresneau M, Marazuela A, Fabra A, Alonso M (2001) Chitosan nanoparticles as delivery systems for doxorubicin. J Controlled Release 73:255–267Google Scholar
  45. Johannes L, Lamaze C (2002) Clathrin-dependent or not: is it still the question? Traffic 3(7):443–451PubMedGoogle Scholar
  46. Keall P, Arnfield M, Arhtur D (2001) An IMRT technique to reduce the heart and lung dose for early stage breast cancer. Int J Radiat Oncol Biol Phys 51(Suppl 1):247Google Scholar
  47. Keynes G (1937) Conservative treatment of cancer of the breast. Br Med J 2:643–649PubMedCentralPubMedGoogle Scholar
  48. Khan F (2003) The physics of radiation therapy, 3rd edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  49. Khan M, Minc L, Nigavekar S, Kariapper M, Nair B (2008) Fabrication of 198Au0 radioactive composite nanodevices and their use for nanobrachytherapy. Nanomed Nanotechnol Biol Med 4:57–69Google Scholar
  50. Kievit F, Wang F, Fang C, Mok H, Wang K (2011) Doxorubicin loaded iron oxide overcome multidrug resistence in cancer in vitro. J Controlled Release 152(1):76–83Google Scholar
  51. Kim T, Kim D, Chung J (2004) Phase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716PubMedGoogle Scholar
  52. Kim D, Rozhkova E, Ulasov I, Bader S, Rajh T, Lesniak W et al (2010) Biofunctioalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat Mater 9(2):165–171PubMedCentralPubMedGoogle Scholar
  53. King T, Bolton J, Kuske R, Fuhrman G, Scroggin T, Jiang X (2000) Long term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectromy for T(is, 1, 2) breast cancer. Am J Surg 180:299–304PubMedGoogle Scholar
  54. Kirkham M, Parton R (2005) Clathrin-independent endocytosis: new insights into caveloae and non-caveolar lipid raft carriers. Biochimica et Biophysica Acta 1746(3):349–363PubMedGoogle Scholar
  55. Kong T, Zheng J, Wang X, Yang J, McQuarrie S (2008) Enhancement of radiation cytotoxicity in breast cancer cells by localized attachment of gold nanoparticles. Small 4(9):1537–1543PubMedGoogle Scholar
  56. Koukourakis M, Giatromanolaki A, Pitiakoudis M, Kouklakis G, Tsoutsou P (2010) Concurrent liposomal cisplatin (lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int J Radiat Oncol Biol Phys 78(1):150–155PubMedGoogle Scholar
  57. Kratz F, Drevs J, Bing G, Stockmar C, Scheuermann K (2001) Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Bioorg Med Chem Lett 11:2001–2006PubMedGoogle Scholar
  58. Kukowska-Latallo J, Candido K, Cao Z, Nigavekar S, Majoros I, Thomas T (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65(12):5317–5324PubMedGoogle Scholar
  59. Larrick J, Wright S (1990) Cytotoxic mechanism of tumour necrosis factor-α. FASEB J. 4:3215–3223PubMedGoogle Scholar
  60. Lesniak W, Kariapper M, Nair B, Tan W, Hutson A, Balogh L et al (2007) Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting αvβ3 integrins. Bioconjug Chem 18:1148–1154PubMedCentralPubMedGoogle Scholar
  61. Leuschner C, Kumar C, Hansel W, Soboyejo W, Zhou J, Hormes J (2006) LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 99:163–176PubMedGoogle Scholar
  62. Li C (2002) Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 54:695–713PubMedGoogle Scholar
  63. Liu C, Wang C, Chien C, Yang T, Chen S, Leng W (2008) Enhanced X-ray irradiation-induced cancer cell damage by gold nanoparticles treated by a new synthesis method of polyethylene glycol modification. Nanotechnology 19:295104PubMedGoogle Scholar
  64. Liu Z, Ran A, Rakhra K, Sherlock S, Goodwin A, Chen X (2009) Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed 48:7668–7672Google Scholar
  65. Loo C, Lowery A, Halas N, West J, Drezek R (2005) Immunotargeted nanoshells or integrated cancer imaging and therapy. Nano Lett 5:709–711PubMedGoogle Scholar
  66. Lowery A, Onishko H, Hallahan D, Han Z (2011) Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Controlled Release 150:117–124Google Scholar
  67. Malam Y, Loizidou M, Seifalian A (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30(11):592–599PubMedGoogle Scholar
  68. Malik N, Evagorou E, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10:767–776PubMedGoogle Scholar
  69. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener J et al (2000) Dendrimers: relationship between structure and biocompatibility in vitro and preliminary studies on the biodistribution of 125-I labelled PAMAM dendrimers in vivo. J Controlled Release 65:133–148Google Scholar
  70. Markman M (2006) Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 7:1469–1474PubMedGoogle Scholar
  71. Mehta V, Algan O, Grien K (2010) Experience with an electronic brachytherapy technique for intracavitary accelerated partial breast irradiation. Am J Clin Oncol 33(4):327–335PubMedGoogle Scholar
  72. Mello R, Callisen H, Winter J, Kagan A, Norman A (1983) Radiation dose enhancement in tumors with iodine. Med Phys 10:75–78Google Scholar
  73. Menard C, Camphausen K, Muanza T (2003) Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rational and early results. Semin Oncol 30(Suppl. 18):63–67PubMedGoogle Scholar
  74. Mesa A, Norman A, Solberg T, Demarco J, Smathers J (1999) Dose distribution using kilovoltage X-rays and dose enhancement from iodine contrast agents. Phys Med Biol 44:1955–1968PubMedGoogle Scholar
  75. Milele E, Spinelli G, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of Paclitaxel (Avraxane® ABI-007) in the treatment of breast cancer. Int J Nanomed 4:99–105Google Scholar
  76. Mille M, Xu G, Rivard M (2010) Comparison of organ doses for patients undergoing balloon brachytherapy of the breast with hdr 192-Ir or electronic sources using monte carlo simulation in a heterogeneous human platform. Med Phys 37(2):662–671PubMedCentralPubMedGoogle Scholar
  77. Misawa M, Takahashi J (2011) Generation of reactive oxygen species induced by gold nanoparticles under X-ray and UV irradiations. Nanomed Nanotechnol Biol Med 7:604–614Google Scholar
  78. Moghimi S, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein binding properties. Prog Lipid Res 42:463–478PubMedGoogle Scholar
  79. Mosesson Y, Mills G, Yarden Y (2008) Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 8(11):835–850PubMedGoogle Scholar
  80. Mukerjee P, Bharracharya R, Wang P, Wang L, Basu S (2005) Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 11(9):3530–3534Google Scholar
  81. Murray CB, Kagan CR, Bawendi MG (1995) Self-organization of CdSe nanocrystallites into three-dimensional quantum dot superlattices. Science 270(1335):1338Google Scholar
  82. Neal A, Torr M, Helyer S (1995) Correlation of breast dose heterogeneity with breast size using 3D CT planning and dose-volume histograms. Radiother Oncol 34:210–218PubMedGoogle Scholar
  83. Nel A, Madler L, Velegol D, Xia T, Hoek E, Somasundaran P et al (2009) Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8:543–557PubMedGoogle Scholar
  84. Nigavekar S, Sung L, Llanes M, El-Jawahri A, Lawrence T, Becker C (2004) 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 21(3):476–483PubMedGoogle Scholar
  85. Oliver M, Chen J, Wong E, Van Dyk J, Perera F (2007) A treatment planning study comparing whole breast radiation therapy against conformal, IMRT and tomotherapy for accelerated partial breast irradiation. Radiother Oncol 82(3):317–323PubMedGoogle Scholar
  86. Pamugula S, Kishore S, Rider B (2005) Radioprotection in mice following oral delivery of amifostine nanoparticles. Int J Radiat Biol 81:251–257Google Scholar
  87. Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R (2007) Dendrimer-modified magnetic nanoparticles enhance efficacy of gene delivery system. Cancer Res 67:8156–8163PubMedGoogle Scholar
  88. Patel K, Li M, Schuh J, Baldeschwieler J (1984) The pharmacological efficacy of a rigid non-phospholipid liposome drug delivery system. Biochim Biophys Acta 797:20–26PubMedGoogle Scholar
  89. Paunesku T, Rajh T, Wiederrecht G, Maser J, Vogt S, Stojicevic N (2003) Biology of TiO2-oligonucleotide nanocomposites. Nat Mater 2:343–346PubMedGoogle Scholar
  90. Perez C, Brady L, Halperin E, Schmidt-Ullrich R (2004) Principles and practice of radiation oncology, 4th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  91. Pierce L, Hutchins L, Green S, Lew D, Gralow J, Livingston R et al (2005) Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23(1):24–29PubMedGoogle Scholar
  92. Rabatic B, Dimitrijevic N, Cook R, Saponjic Z, Rajh T (2006) Spatially confined corner defects induce chemical functionality of TiO2 nanorods. Adv Mater 18(8):1033–1037Google Scholar
  93. Rahman W, Bishara N, Ackerly T, He C, Jackson P, Wong C et al (2009) Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy. Nanomed Nanotechnol Biol Med 5:136–142Google Scholar
  94. Recht A (2003) Integration of systemic therapy and radiation therapy for patients with early-stage breast cancer treated with conservative surgery. Clin Breast Cancer 4:104–113PubMedGoogle Scholar
  95. Reed J, Miyashita T, Takayama S, Wang H, Sato T, Krajewski S et al (1996) Bcl-2 family proteins: regulators of cell death in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23–32PubMedGoogle Scholar
  96. Rivera E (2003a) Liposmal anthracyclines in metatstaic breast cancer: clinical update. Oncologist 8(Suppl 2):3–9PubMedGoogle Scholar
  97. Rivera E (2003b) Current status of liposomal antracycline therapy in metastatic breast cancer. Clin Breast Cancer 4:S76–S83PubMedGoogle Scholar
  98. Robar J, Ribbio S, Martin M (2002) Tumour dose enhancement using modified megavoltage photon beams and contrast media. Phys Med Biol 47:2433–2449PubMedGoogle Scholar
  99. Sabbatini P, Aghajanian C, Dizon D (2004) Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22:4523–4531PubMedGoogle Scholar
  100. Schweitzer A, Howell C, Jiang Z (2009) Physico-chemical evaluation of rationally designed melanins as novel nature-inspired radioprotectors. PLoS ONE 4:e7229PubMedCentralPubMedGoogle Scholar
  101. Schweitzer A, Revskaya E, Chu P, Pazo V, Friedman M, Nosanchuk J et al (2010) Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer. Int J Radiat Oncol Biol Phys 78(5):1494–1502PubMedCentralPubMedGoogle Scholar
  102. Sekhon B, Kamboj S (2010a) Inorganic nanomedicine—part 2. Nanomed Nanotechnol Biol Med 6:612–618Google Scholar
  103. Sekhon B, Kamboj S (2010b) Inorganic nanomedicine—part 1. Nanomed Nanotechnol Biol Med 6:516–522Google Scholar
  104. Sini P, Wyder L, Schnell C, O’Reilly T (2005) The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 11:4521–4532PubMedGoogle Scholar
  105. Small W (2003) Radiation therapy oncology group C-0116 trial. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the radiation therapy oncology group C-0116 trial. Semin Oncol 30(Suppl. 18):68–71PubMedGoogle Scholar
  106. Steinhauser I, Spankuch B, Strebhardt K, Langer K (2006) Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27:4975–4983PubMedGoogle Scholar
  107. Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto J, Tasciotti E, Robertson F et al (2009) Nanotechnology for breast cancer therapy. Biomed Microdevices 11:49–63PubMedGoogle Scholar
  108. Taylor-Pashow K, Rocca J, Huxford R, Lin W (2010) Hybrid nanomaterials for biomedical applications. Chem Commun 46:5832–5849Google Scholar
  109. Tomalia D, Baker J, Dewald M, Hall G, Kallos S, Martin J et al (1985) A new class of polymers: starburst-dendritic macromolecules. Polym J 17:117–132Google Scholar
  110. Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosome or mitochondria. Genes Cells 3(11):687–707Google Scholar
  111. Vasey P, Kaye S, Morrison T, Twelves C, Wilson P, Duncan P, Phase I (1999) Clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)-methacrylaminde copolymer doxorubicin]: first member of a new class of chemotherapeutic agents–drug-polymer conjugates. Clin Cancer Res 5:83–94PubMedGoogle Scholar
  112. Veronesi U, Marubini E, Marian L (2001a) Radiotherapy after breast-preserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12:997–1003PubMedGoogle Scholar
  113. Veronesi U, Oreechia R, Luini A (2001b) A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 37:2178–2183PubMedGoogle Scholar
  114. Vinci F, Baglan K, Kestin L (2001) Accelerated treatment of breast cancer. J Clin Oncol 19(7):1993–2001Google Scholar
  115. Vivero-Escoto J, Slowing I, Trewyn B, Lin V (2010) Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 6(18):1952–1967PubMedGoogle Scholar
  116. Wang A, Yuet K, Zhang L, Gu F, Huynh-Le M (2010) ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomed 5(3):361–368 LondonGoogle Scholar
  117. Wazer D, Berle L, Graham R (2002) Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys 53(4):889–897PubMedGoogle Scholar
  118. Werner M, Copp J, Karve S, Cummings N, Sukumar R, Li C (2011) Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependant on the timing of radiotherapy. ACS Nano 5(11):8990–8998PubMedCentralPubMedGoogle Scholar
  119. Wisse E, Braet F, Luo D (1996) Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol 24:100–111PubMedGoogle Scholar
  120. Wu A, Paunesku T, Zhang Z, Vogt S, Lai B, Maser J (2011) A multimodal nanocomposite for biomedical imaging. AIP Conf Proc 1365:379–383PubMedCentralPubMedGoogle Scholar
  121. Xie J, Chen K, Huang J, Lee S, Wang J (2010) PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 31:3016–3022PubMedCentralPubMedGoogle Scholar
  122. Yoo H, Oh J, Lee K, Park T (1999) Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 16:1114–1118PubMedGoogle Scholar
  123. Yoo H, Lee K, Oh J, Park T (2000) In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Controlled Release 68(3):419–431Google Scholar
  124. Yuan F, Dellian M, Fukumua D (1995) Vascular permeability in the human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Radiation OncologyGeorgia Regents UniversityAugustaUSA

Personalised recommendations